12
Jun

A Cuban vaccine might some day turn lung cancer into a chronic disease

BUFFALO, N.Y. – The first patients in a clinical trial at Roswell Park Cancer Institute have begun receiving monthly doses of CIMAvax-EGF, a Cuban lung cancer vaccine that U.S. researchers say shows promise in preventing the recurrence of lung cancer — the leading cause of cancer deaths in the United States.

The Roswell trial, which was authorized by the U.S. Food and Drug Administration last fall, is the first time that a Cuban-made therapy has been tested on U.S. patients. CIMAvax has already undergone extensive clinical trials in Cuba and around the world and is an approved therapy for treatment of lung cancer not only on the island but also in Colombia, Peru, Paraguay, and Bosnia and Herzegovina.

Read Full Story Here >>